INMB - INmune rises 7% after company files application to begin trial of cancer treatment

2023-04-03 10:48:24 ET

• INmune Bio ( NASDAQ: INMB ) is trading ~7% higher after it had submitted an investigational new drug application to the U.S. Food and Drug Administration (FDA) for INKmune to treat metastatic castration-resistant prostate cancer.
• The 6-month trial will test three doses of INKmune and is expected to take place in four or more medical centers in the U.S, and will enroll about 30 patients.
• The goal of the trial is to test the safety of INKmune and demonstrate the ability to attack prostate cancer.
• The company said it expects a period of consultation with the FDA prior to initiating the planned trial.
• Press Release

For further details see: